Introduction: Texas poison centers identified carisoprodol as a skeletal muscle relaxant that is subject to abuse, and this investigation explores the abuse reported by Texas poison centers.
INTRODUCTION
Carisoprodol (N-isopropyl-2-methyl-3-propyl-1,3-propanediol dicarbamate; N-isopropylmeprobamate) is a skeletal muscle relaxant. Although carisoprodol itself is not controlled on the federal level, its active metabolite, meprobamate, is an addictive sedative and a Schedule IV controlled substance. Carisoprodol is marketed under a variety of brand names such as Soma ® , Carisoma ® , Flexartal ® , Rela ® , Sanoma ® , Sodol ® , Somadril ® , Soprodol ® , and Soridol ® ; and it serves as the only active ingredient or in combination with other drugs such as aspirin and codeine. The method of action of carisoprodol is unclear [1] . In the United States in 2003, carisoprodol ranked thirty-sixth among generic drugs by number of prescriptions (9, 536 ,000 prescriptions) and thirty-second by retail dollars ($283,336,000) [2, 3] .
Abuse of carisoprodol, either alone or in combination with other substances, is known to occur [4] [5] [6] [7] . In 1997 in Cincinnati, Ohio, carisoprodol was the fifth most common diverted prescription drug according to the police and eighth most common abused prescription drug according to the local poison center [8] . Carisoprodol abuse is important because use of the drug may result in impairment of driving ability and may lead to dependency [9] [10] [11] [12] . Carisoprodol may result in a variety of adverse effects that impact various organ systems; such as: the central nervous system (drowsiness, lightheadedness, dizziness, fatigue, loss of motor coordination, insomnia, stupor, coma), cardiovascular function (tachycardia, facial flushing), respiratory function (dyspnea, respiratory depression), musculoskeletal function (hypertonia, tremor), skin responses (rash, hives), gastrointestinal responses (nausea, vomiting), and ocular function (blurred or burning vision, nystagmus) [1, 13] . Carisprodol overdose has also been reported to result in an unusual movement disorder involving agitation, hypertonia, and myoclonic encephalopathy [14, 15] . The effects of carisoprodol may be potentiated with the use of other substances such as alcohol or other central nervous system depressants [1] . Deaths have been reported with carisoprodol use [13, 16] .
The objective of this investigation was to describe the patterns of carisoprodol abuse identified by six poison centers over a recent six-year period. Poison centers receive calls involving substance abuse as well as drug identification (ID) calls, a portion of which represent calls by potential abusers wanting to confirm the drug and a portion of calls from law enforcement officials wanting to identify confiscated substances [17] [18] [19] . Drug ID calls can also provide an indirect measure of substance abuse in a known population.
MATERIALS AND METHODS
Data for this retrospective study were obtained from the six poison centers that comprise the Texas Poison Center Network (TPCN). All six poison centers use the same Toxicall software and the Toxic Exposure Surveillance System (TESS) database to collect information from calls. Cases included all calls, involving carisoprodol, received by the TPCN from 1998 to 2003.
The distribution of cases was identified by major type of call (human exposures, animal exposures, drug IDs, or other information requests). Until 2002, information on the source of a drug ID call (whether from a public citizen, health care provider, or law enforcement official) was not collected, so the source of drug ID calls was not evaluated in this study. The number of cases by year was determined by four categories of calls: (1) all calls, (2) all drug ID calls, (3) all human exposure calls, and (4) those human exposure calls involving abuse. Abuse calls were defined as those human exposure calls involving intentional misuse or abuse of carisoprodol and excluded unintentional misuse and suspected suicide calls. These four categories were then examined for annual trends and statistical significance determined by calculating the Chi-square test for trend.
Texas is divided into eleven Public Health Regions (PHRs). The distribution of carisoprodol drug ID and abuse calls by PHR was determined and compared to the total population distribution based on information from the 2000 Census.
Abuse calls were then compared to all other human exposure calls with respect to patient gender, patient age, exposure site, management site, and medical outcome. The groupings within these variables were based on the categories in the TESS database. The medical outcome categories were defined as follows: no effect (no symptoms due to exposure), minor effect (some minimally troublesome symptoms), moderate effect (more pronounced, prolonged symptoms), major effect (symptoms that are life-threatening or cause significant disability or disfigurement), and death.
All variables were unavailable for all of the relevant cases, so the sum of the subcategories might not equal the total number of calls. Comparisons between abuse calls and all other human exposure calls were evaluated for statistical significance by calculating the ratio of the rate among abuse calls to the ratio of the rate among other exposure calls and the 95% confidence intervals by Poisson probability using the Fisher's exact text.
RESULTS
The TPCN received 11,184 carisoprodol calls from 1998 to 2003. Of these calls, 5,570 (49.8%) were human exposures, 54 (0.5%) animal exposures, 4,871 (43.6%) drug IDs, and 689 (6.2%) other information. Of the human exposure calls, 936 (16.8%) were abuse calls. Table 1 presents the distribution of carisoprodol calls by year. All examined categories of calls increased over the six-year period. Table 2 contains the distribution of drug ID and abuse calls for carisoprodol by PHR. The geographic distribution of abuse calls differed from geographic distribution of drug ID calls, and distribution of both types of calls differed from that of the total population, with many of these differences being statistically significant. For example, although PHR 3 contains 26.3% of the Texas population, it accounted for 7.5% of drug ID calls and 17.6% of abuse calls. And while PHRs 4-7 contains 42.8% of the state's population, these PHRs reported 76.5% of all drug ID calls and 63.8% of all abuse calls.
Of the 936 carisoprodol abuse calls, 362 (38.7%) did not involve other substances. Of the 4,634 other human carisoprodol exposure calls, 1,901 (41.0%) did not involve other substances (rate ratio 0.94, 95% confidence interval 0.84-1.06). Table 3 shows the distribution of carisoprodol abuse calls and other human exposure calls by various demographic and clinical factors. Although abuse calls were evenly distributed between male and female patients, other human exposure calls were significantly more likely to involve females. And while the majority of both types of exposure calls involved adult patients, the proportion of abuse calls represented by patients from ages 13 to 19 years was substantially greater than other human exposure calls.
Both abuse and other human exposure calls predominantly came from the patient's own residence. However, of other exposure sites, a much higher proportion of abuse calls came from other residences, schools, and public areas.
The pattern of management site was similar for both types of human carisoprodol exposure calls. However, among those human exposure calls with a known medical outcome, a substantially higher percentage of abuse calls involved minor effects while a greater proportion of other human exposure calls involved effects that varied from moderate outcomes to death.
DISCUSSION
This investigation described the epidemiology of carisoprodol abuse calls to Texas poison centers during a recent six-year period. Such information is important because carisoprodol is a commonly prescribed drug in the United States. However, carisoprodol use can be associated with impairment of driving ability, dependency, and a number of adverse effects. Abuse of this drug could cause serious problems. In spite of this fact, epidemiologic information on carisoprodol abuse is limited.
There is a primary limitation to this investigation: reporting carisoprodol exposures to poison centers in Texas is strictly voluntary, and poison centers do not actively seek out carisoprodol exposures. The number of carisoprodol exposures, especially those involving potentially adverse effects or abuse, in Texas is unknown. But those calls received by the TPCN are expected to represent only a fraction of the total. Thus there is potential for bias in the present analysis. However, the current investigation may inspire subsequent research not subject to this limitation.
Although there was an increase in carisoprodol calls of all types examined during the six-year period of the study, this annual trend was particularly strong for drug ID and abuse calls. Drug ID and abuse calls were 216.6% higher in 2003 than in 1998; they represented 43.2% of all calls in 1998 and 61.2% in 2003. This would indicate that carisoprodol abuse is becoming an increasing problem in Texas.
The geographic distribution of carisoprodol drug ID calls and abuse calls was not consistent with the population distribution within the state. Of note, the population of PHRs 4-7 (east and central Texas, including the major cities of Houston and Austin) accounted for a disproportionate number of calls based on the size of their population. This finding suggests that carisoprodol abuse is a greater problem in the eastern part of Texas than the rest of the state and that carisoprodol abuse education and prevention activities should be concentrated in these areas.
It might be suggested that drug ID calls to poison centers can serve as a measure of abuse of these substances within the population [17] . The facts that carisoprodol drug ID and abuse calls increased disproportionately over the period of this investigation appear to bear this out. However, this suggestion is tempered by the observation that the geographic distribution of drug ID and abuse calls was not consistent, with some areas reporting higher than expected drug ID calls but reporting lower than expected abuse calls and vice versa.
The provision of drug IDs by poison centers is somewhat controversial [20] . Providing drug IDs requires use of limited poison center resources, and some may speculate that it may contribute to the abuse of substances [17] . Currently, the TPCN is evaluating which drug ID call policy would best serve the needs of the poison centers.
Although roughly the same proportion of carisoprodol abuse and other human exposure calls involved the presence of other substances, abuse calls tended to differ from other human exposure calls in various ways. When compared to other human exposures, carisoprodol abuse was much more likely to involve males, adolescents, and occur at other residences, schools, or in public areas. Moreover, although abuse and other human exposure calls were similar with respect to management site, other human carisoprodol exposures were more likely to involve serious medical outcomes. These differences suggest that the education and prevention strategies and management for carisoprodol abuse should differ from those for other adverse human exposures to carisoprodol.
In summary, carisoprodol abuse is increasing in Texas and is more common in the eastern and central part of the state. Carisoprodol abuse is much more likely than other types of adverse carisoprodol exposures to involve males and adolescents and to occur in schools and public areas and less likely to involve adverse medical outcomes.
